Alcohol
Half-Life (t½) PO: 15m · IV: 15m
Formula C2H6O
Molecular Weight 46.07 g/mol
Aliases Ethanol, EtOH Pharmacological Mechanism GABA-A positive allosteric modulator + NMDA antagonist + 5-HT3 agonist + acute DA release. Metabolised by ADH → acetaldehyde (toxic) → ALDH → acetate. East Asian populations often carry ALDH2 *2 variant → acetaldehyde accumulation → facial flushing + increased cancer risk. Zero-order kinetics above ~0.08 g/L (saturable ADH).
Half-Life & Elimination Curve (PO: 15m · IV: 15m) 100% 50% 25% 12.5% 0% 0h 0×t½ 15m 1×t½ 30m 2×t½ 45m 3×t½ 1h 4×t½ 1.25h 5×t½ 0×t½ (0h): 100% remaining (~267 mg/L) 1×t½ (15m): 50% remaining (~133 mg/L) 2×t½ (30m): 25% remaining (~66.7 mg/L) 3×t½ (45m): 12.5% remaining (~33.3 mg/L) 4×t½ (1h): 6.3% remaining (~16.7 mg/L) 5×t½ (1.25h): 3.1% remaining (~8.33 mg/L) Elimination (PO)
0×t½ 0h 100% (267 mg/L) 1×t½ 15m 50% (133 mg/L) 2×t½ 30m 25% (66.7 mg/L) 3×t½ 45m 12.5% (33.3 mg/L) 4×t½ 1h 6.3% (16.7 mg/L) 5×t½ 1.25h 3.1% (8.33 mg/L) Dosing Guidelines Oral (PO): Typical 14 gIntravenous (IV): Typical 14 gPharmacokinetic Parameters Oral (PO): Bioavailability (F): 80% · Volume of Distribution (Vd): 42 L [PMID 11003200 ]Intravenous (IV): Bioavailability (F): 100% · Volume of Distribution (Vd): 42 L [PMID 11003200 ]Pathways It Modulates Target Organ Systems Interactions Acetaminophen (major): Chronic ethanol induces CYP2E1 (CL ↑73% in alcoholics, Girre 1994 chlorzoxazone probe). APAP is only ~5–10% cleared by CYP2E1 (the NAPQI/toxic pathway), so the total-clearance bump is small (~7%). The clinical concern is glutathione depletion + raised NAPQI causing hepatotoxicity at lower APAP doses — not kinetic AUC shift. Limit APAP ≤2 g/d in heavy drinkers.Chemical Structure & Identifiers InChIKey: LFQSCWFLJHTTHZ-UHFFFAOYSA-NSMILES: CCOReferences Directory Compounds Registry Human Biology Hub